Rite Aid Corporation (RAD) Ugly earnings. No turnaround here. Falls to $2.71 from 52-week high of $6.74.
MBIA (MBI) Concerns about CDOs being insured here. Falls to $18.84 from 52-week high of $76.02.
SLM (SLM) Still falling after comments about tough 2008 and possible dividend cut. Down to $19.84 from 52-week high of $58.
Altus Pharmaceuticals (ALTU) Partnership with Genentech (DNA) broken off. Sells off to $4.80 from 52-week high of $20.50.
Amicus Therapeutics (FOLD) Wall St. views new drug as less than competitive to current offerings. Shares drop to $9.20 from 52-week high of $18.22.
Array Biopharma (ARRY) Clinical trial fails. Drops to $7.81 from 52-week high of $14.59
Citigroup (C) Fresh concerns about mortgage risks. Drops to $29.34 from 52-week high of $57.
Douglas A. McIntyre
Douglas A. McIntyre
In 20 Years, I Haven’t Seen A Cash Back Card This Good
After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.
A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.
Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.